Dosage and administration
Before, during and/or after pregnancy, one tablet daily with food or as directed by a physician.
Before, during and/or after pregnancy, one tablet daily with food or as directed by a physician.
Altrixa OB Tablets - Dispensed by Prescription
Serving Size: 1 Tablet Servings Per Container: 30 | ||
Each Tablet Contains: | %DV | |
Vitamin A (as beta-carotene) | 300 mcg RAE | 66% |
Vitamin C (as ascorbic acid) | 125 mg | 140% |
Vitamin D3 (as cholecalciferol) | 12.5 mcg | 30% |
Vitamin E (as dl-alpha-tocopheryl acetate) | 4.5 mg | 33% |
Vitamin B6 (as pyridoxine HCl) | 20 mg | 1117% |
Folate (From 588 mcg folic acid and 442 mcg L-5 MTHF ca salt) | 1750 mcg DFE | 437.5% |
Vitamin B12 (as cyanocobalamine) | 0.03 mg | 650% |
Biotin | 30 mg | 10% |
Calcium (from calcium carbonate) | 100 mg | 7.5% |
Iron (as ferrous fumarate) | 15 mg | 83% |
Iodine (as potassium iodide) | 150 mcg | 100% |
Magnesium (as magnesium oxide) | 20 mg | 5% |
Thiamin (as thiamin HCI) 1.4 mg 100% | ||
** Daily Values (DV) not established.
OTHER INGREDIENTS: Microcrystalline cellulose, powdered cellulose, silica, vegetable steric acid, croscarmellose sodium, vegetable magnesium stearate, coating (hypromellose, hydroxypropyl cellulose, titanium dioxide, polyehylene glycol).
Altrixa OB Tablets is a prescription dietary supplement for use throughout pregnancy, during the postnatal period for both lactating and non-lactating mothers, and throughout the childbearing years.
Prenate Max Tablets may be useful in improving the nutritional status of women prior to conception.
Altrixa OB Tablets are contraindicted in patients with a known hypersensitivity to any of the contained ingredients. Do not take this product if you are presently taking mineral oil, unless directed by a licensed medical practitioner.
Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. In the case of accidental overdose, call a doctor or poison control center immediately.
Allergic sensitization has been reported following both oral and parenteral administration of folic acid.
You may report side effects by calling Allegis Pharmaceuticals, Inc at 1-866-633-9033 or the FDA by calling 1-800-FDA-1088.
Before, during and/or after pregnancy, one tablet daily with food or as directed by a physician.
Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress. Prenate Max Tablets should only be used under the direction and supervision of a licensed medical practioner.
For use under the supervision of a licensed medical practitioner. Dispense in a tight, light resistant container as defined in the USP/NF in a child-resistant closure.
How Supplied
Altrixa OB Talets are available as white tablets with "225" embossed and are available in 30 count bottles (28595-721-30*).
Manufactured in the USA for:
Allegis Pharmaceuticals, Inc.
Canton, MS 39046
Rev 05/2025
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
This product is not an Orange Book Product.
Dispense by Prescrition**
*Allegis Pharmaceuticals, Inc. does not represent these product codes to be National Drug Codes (NDC). Product codes are formated according to standard industry practice, to meet the formatting requirements by pedigree reporting and supply-chain control including pharmacies.
** This product is a prescription-folate with or without other dietary ingredients that - due to increased folate levels increased risk associated with masking of B12 deficiency (pernicious anemia) requires administratin under the care of a licensed medical practitioner (61 FR 8760).1-3 The most appropriate way to ensure pedigree reporting consistent with these regulatory guidelines and safety monitoring is to dispense this product only by prescription. This is not an Orange Book product. This product may be administered only under a physician's supervision and all prescriptions using this product shall be pursuant to state statutes as applicable. The ingredients, indication or claims of this product are not to be construed to be a drug claims.
1. Federal Register Notice of August 2, 1973 (38 FR 20750)
2. Federal Register Notice of October 17, 1980 (45 FR 69043, 69044)
3. Federal Register Notice of March 5, 1996 (61 FR 8760)
Store at 20°-25°C (68°-77°F) excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature.] Protect from light
and moisture.
Tamper evident: Do not use if seal is broken or missing.
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 28595-721-30 | EA - Each | 28595-721 | dc3de7c1-acdc-4e38-81cb-a7cc1c095c76 | 1 | 2025-07-08 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 28595-721 | 28595-721-30 |
Every source-derived ingredient row is available through these pages.
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ascorbic Acid | ASCORBIC ACID | Renova Pharmaceuticals LLC | a6481bae-2397-44c7-a51d-4f47ad91bd2c | 2026-08-19 | Warnings, Adverse reactions | ASCORBIC ACID |
| Ascor | ASCORBIC ACID | McGuff Pharmaceuticals, Inc. | 388aad52-fc01-4784-9791-1dbc80c69306 | 2026-05-29 | Warnings, Adverse reactions | ASCORBIC ACID |
| Ascorbic Acid | ASCORBIC ACID | Fresenius Kabi USA, LLC | 1606e29f-0e80-4069-b688-daab9cbff20a | 2025-12-17 | Warnings, Adverse reactions | ASCORBIC ACID |
| Skin Renewing Serum | ASCORBIC ACID | Guangzhou Danting Bath&Body Care Industry Co. Ltd | 396c2a8d-ac95-cbef-e063-6294a90aff39 | 2025-08-23 | Warnings | ASCORBIC ACID |
Adverse event summaries are temporarily unavailable. Other product information remains available.